Crossmark

ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer

Crossref DOI link: https://doi.org/10.1007/s10120-020-01096-y

Published Online: 2020-06-22

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fu, Tao

Ji, Ke

Jin, Li

Zhang, Ji

Wu, Xiaojiang

Ji, Xin

Fan, Biao

Jia, Ziyu

Wang, Anqiang

Liu, Jiaen

Bu, Zhaode

Ji, Jiafu https://orcid.org/0000-0003-3304-9428
Funding

Funding for this research was provided by:

Beijing Municipal Administration of Hospital Clinical Medicine Development of Special Funding Support (ZYLX201701)
License Information

Text and Data Mining valid from 2020-06-22

Version of Record valid from 2020-06-22
More Information

Article History

Received: 17 December 2019

Accepted: 28 May 2020

First Online: 22 June 2020

Compliance with ethical standards

:

: The authors declare that they have no competing interest.

: With the informed consents signed by all patients, this study had received the approval of the Ethics Committee of Peking University Cancer Hospital and Institute.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below